MESA Treatment for NK/T Cell Lymphoma

Inclusion Criteria: * Pathological diagnosis is NK/T cell lymphoma； * At least one objective evaluation ( measurable ) lesions * Age 15 \~ 60 years old, men and women are not limited * ECOG(Eastern Cooperative Oncology Group）performance status 0\~3，Expected to survive more than 3 months; * Heart, kidney function in the normal range * Liver function: transminase\< 2 times the normal value * pregnancy tests of women childbearing age must be negative; Men and women agree to use effective contraception during the treatment and the following year * Before the test sign the written informed consent Exclusion Criteria: * The early use of methotrexate or/and L-asparaginase; * Pregnant or nursing, psychiatric patients complicated with malignant tumor * At the same time the application of other trial drug, drug contraindications exist in research; * Serious infection or metabolic diseases * Liver dysfunction, serum direct bilirubin, indirect bilirubin, transaminase 2 times higher than normal; serum total protein or albumin below normal; * Renal insufficiency, creatinine clearance rate was 2 times higher than normal, especially the creatinine clearance rate is less than 30ml/min; * Before entering the group, blood: White blood cell\< 3×10E9/L; absolute neutrophil count\<1.5×10E9/L; platelet\<100×10E9/L ( bone marrow is not violated ); platelet count \<75×10E9/L ( bone marrow invasion ); hemoglobin\<100g/L. * In the 6 months before entering the group, patients with uncontrolled or serious cardiovascular diseases, including myocardial infarction, III-IV class heart failure, uncontrolled angina or clinically significant pericardial disease, and diabetes and phlebitis; * HIV antibody positive, HBsAg positive after antiviral HBV(hepatitis B virus) DNA titer in 104copies/ml the following groups. HIV antibody positive, HBsAg+ and DNA titer in 104copies/ml after antiviral HBV therapy * Coagulation abnormalities.